Bioavailability Development Drug Delivery Trials 
Roots Analysis
MARCH 2, 2022
Interestingly, recent advances in this domain have led to the development of several treatment strategies that, according to developers, exhibit the necessary capabilities to overcome challenges posed by traditional oral protein formulations and peptide-based therapies. Oral Protein / Peptide-based Drugs.
XTalks
JUNE 14, 2023
The clinical trials consistently showed significant therapeutic improvements in ocular surface damage and associated symptoms, while pioneering visual function improvement analysis”, said John D. “The Attendees will understand best practices for novel drug delivery design and development. What Is Dry Eye Disease?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
MAY 21, 2024
In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.
XTalks
MAY 23, 2024
Companies specializing in dermatology and skincare have developed a range of products aimed at protecting the skin from harmful UV rays. These include broad-spectrum sunscreens, protective clothing and innovative skincare products developed using antioxidants and other protective agents. How is Medicus Pharma innovating in this space?
Roots Analysis
SEPTEMBER 1, 2023
The integration of the blue ocean strategy in healthcare landscape, often known as blue ocean therapy, and its application in medical product development, such as blue ocean medical products, is the silver lining that can revolutionize the industry. This strategy is not a silver bullet; it’s a calculated voyage into uncharted waters.
XTalks
AUGUST 30, 2022
Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. CNS drugs treat a range of neurologic and psychiatric disorders, such as psychosis, depression, Parkinson’s disease, multiple sclerosis and epilepsy.
The Pharma Data
NOVEMBER 26, 2020
This novel nanoparticle formation technology provides hope for improving the possibilities and probabilities of developing better medicines for patients and it expands Nanoform’s reach into the growing biological market. ” Prof. ” Prof. Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.
Expert insights. Personalized for you.
52 
Let's personalize your content